Finally, separate from the specific target in PBMCs, a profound degradation of total RanGTPase is observed in whole blood from ALS patients but not in healthy controls, and is substantially rescued after 72 h of treatment with ALS-active assembly modulators. Here, RAN is linked to amyotrophic lateral sclerosis.